232 related articles for article (PubMed ID: 21482708)
1. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
Martinez-Lopez J; Blade J; Mateos MV; Grande C; Alegre A; García-Laraña J; Sureda A; de la Rubia J; Conde E; Martinez R; de Arriba F; Viguria MC; Besalduch J; Cabrera R; Gonzalez-San Miguel JD; Guzman-Zamudio JL; Gomez del Castillo MC; Moraleda JM; García-Ruiz JC; San Miguel J; Lahuerta JJ; ;
Blood; 2011 Jul; 118(3):529-34. PubMed ID: 21482708
[TBL] [Abstract][Full Text] [Related]
2. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
6. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
7. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
8. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
9. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
11. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors.
Kumar L; Cyriac SL; Tejomurtula TV; Bahl A; Biswas B; Sahoo RK; Mukherjee A; Sharma O
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):32-41. PubMed ID: 23085487
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Lee CK; Badros A; Barlogie B; Morris C; Zangari M; Fassas A; van Rhee F; Cottler-Fox M; Jacobson J; Thertulien R; Muwalla F; Mazher S; Anaissie E; Tricot G
Exp Hematol; 2003 Jan; 31(1):73-80. PubMed ID: 12543109
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
15. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
Kapoor P; Kumar SK; Dispenzieri A; Lacy MQ; Buadi F; Dingli D; Russell SJ; Hayman SR; Witzig TE; Lust JA; Leung N; Lin Y; Zeldenrust SR; McCurdy A; Greipp PR; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2013 Dec; 31(36):4529-35. PubMed ID: 24248686
[TBL] [Abstract][Full Text] [Related]
16. Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Chim CS; Liu H; Lie AK; Chan EY; Ho S; Wong M; Kwong YL
Hematol Oncol; 2014 Dec; 32(4):205-11. PubMed ID: 24473998
[TBL] [Abstract][Full Text] [Related]
17. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Ong SY; de Mel S; Chen YX; Ooi MG; Surendran S; Lin A; Koh LP; Linn YC; Ho AY; Hwang WY; Phipps C; Loh SM; Goh YT; Tan D; Chng WJ; Gopalakrishnan SK
Bone Marrow Transplant; 2016 Jul; 51(7):933-7. PubMed ID: 26974274
[TBL] [Abstract][Full Text] [Related]
18. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of Curative Efficacy of Different Chemotherapy Regimen Combined with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on Multiple Myeloma].
Wang CB; Bai H; Xi R; Pan YZ; Wu T; Xu SF; Zhang Q; Zhou JM; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1675-1680. PubMed ID: 30501703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
